Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
20 mg Tasimelteon vs Placebo in Totally Blind Subjects With Non-24-Hour Sleep-Wake Disorder
DRKS00003187Phase 3Completed
- Sponsor
- Vanda Pharmaceuticals Inc.
- Start
- Jul 2011
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in Non-24-hour sleep-wake disorder (N24SWD) comparing Tasimelteon 20 mg with Placebo (2 arms). Started Jul 2011; status: completed.
02
Drugs
tasimelteon
03
Conditions
Non-24-hour sleep-wake disorder (N24SWD)
Beyond the preview
Go deeper on DRKS00003187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00003187.